Allos granted Mundipharma exclusive rights outside of the U.S. and Canada to co-develop and commercialize cancer therapy Folotyn pralatrexate

Allos Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Mundipharma International Ltd.

U.K. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced